He will lead CD36 development programs in various chronic inflammation-based diseases such as dry age-related macular degeneration, atherosclerosis and non-alcoholic steatohepatitis.
Chipperton is a serial life sciences entrepreneur, and comes with a proven track-record, most notably as 2008 co-founder and CEO of Profound Medical Inc., where in a four-year span he raised more than CDN 16m of venture capital financing, and the company subsequently went public in 2015, on the TSX Venture exchange (TSX: PRN) (OTCQX: PRFMF).
He currently sits on the boards of Intronix and Angel Investors Ontario. He is deeply experienced in rapidly transitioning academic research into established, well-financed clinical stage companies.
Mperia Therapeutics is the CD36 Therapeutics company which focuses on macrophage-driven inflammation.
The technology basis resides in highly specific CD36 receptor cyclic peptides which modulate the inflammasome in addition to modifying macrophages' metabolic dysfunction with outstanding anti-inflammatory response.
Mperia holds exclusive rights to various highly efficacious CD36 receptors ligands against dAMD and atherosclerosis.
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial